|Systematic (IUPAC) name|
Trimegestone (INN) (brand name Ondeva), also known as 21-hydroxypromegestone, is a 19-norprogesterone derivative and steroidal progestin which was introduced in France in 2001 and is used as a hormonal contraceptive and in hormonal replacement therapy for postmenopausal symptoms. It is a very potent and pure progestogen, lacking activity at other steroid hormone receptors. Trimegestone has been described as both "fourth generation" and "second generation" (due to the use of different progestin generational schemes; in any case, it is considered to be of the most recent generation).
- C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 2063–. ISBN 978-0-412-46630-4.
- Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 208–. ISBN 978-3-527-62330-3.
- Winnifred Cutler (30 March 2009). Hormones and Your Health: The Smart Woman's Guide to Hormonal and Alternative Therapies for Menopause. John Wiley & Sons. pp. 43–. ISBN 978-0-470-52553-1.
- Annual Reports in Medicinal Chemistry. Academic Press. 31 December 2012. pp. 273,647. ISBN 978-0-12-397214-9.
- Ramesh N. Patel (26 September 2006). Biocatalysis in the Pharmaceutical and Biotechnology Industries. CRC Press. pp. 288–. ISBN 978-1-4200-1937-7.
- Sitruk-Ware R (2004). "New progestogens: a review of their effects in perimenopausal and postmenopausal women". Drugs Aging 21 (13): 865–83. PMID 15493951. doi:10.2165/00002512-200421130-00004.